Aloyz R - Search Results

1

Pharmacological targeting of eIF4E in primary CLL lymphocytes.

Martinez-Marignac V, Shawi M, Pinedo-Carpio E, Wang X, Panasci L, Miller W, Pettersson F, Aloyz R. Martinez-Marignac V, et al. Among authors: aloyz r. Blood Cancer J. 2013 Sep 13;3(9):e146. doi: 10.1038/bcj.2013.43. Blood Cancer J. 2013. PMID: 24036945 Free PMC article. No abstract available.

2

The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.

Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L. Amrein L, et al. Among authors: aloyz r. Int J Cancer. 2013 Jul;133(1):247-52. doi: 10.1002/ijc.27989. Epub 2013 Jan 15. Int J Cancer. 2013. PMID: 23238639 Free PMC article.

3

Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.

Shawi M, Chu TW, Martinez-Marignac V, Yu Y, Gryaznov SM, Johnston JB, Lees-Miller SP, Assouline SE, Autexier C, Aloyz R. Shawi M, et al. Among authors: aloyz r. PLoS One. 2013 Jul 29;8(7):e70428. doi: 10.1371/journal.pone.0070428. Print 2013. PLoS One. 2013. PMID: 23922990 Free PMC article.

4

Imatinib sensitizes CLL lymphocytes to chlorambucil.

Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L. Aloyz R, et al. Leukemia. 2004 Mar;18(3):409-14. doi: 10.1038/sj.leu.2403247. Leukemia. 2004. PMID: 14712290

5

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.

Sahebjam S, Aloyz R, Pilavdzic D, Brisson ML, Ferrario C, Bouganim N, Cohen V, Miller WH Jr, Panasci LC. Sahebjam S, et al. Among authors: aloyz r. Br J Cancer. 2011 Oct 25;105(9):1342-5. doi: 10.1038/bjc.2011.402. Epub 2011 Oct 4. Br J Cancer. 2011. PMID: 21970880 Free PMC article.

6

Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells.

Davidson D, Grenier J, Martinez-Marignac V, Amrein L, Shawi M, Tokars M, Aloyz R, Panasci L. Davidson D, et al. Among authors: aloyz r. Invest New Drugs. 2012 Aug;30(4):1736-42. doi: 10.1007/s10637-011-9678-5. Epub 2011 May 13. Invest New Drugs. 2012. PMID: 21567185

7

Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy.

Amrein L, Davidson D, Shawi M, Petruccelli LA, Miller WH Jr, Aloyz R, Panasci L. Amrein L, et al. Among authors: aloyz r. Leuk Res. 2011 Aug;35(8):1080-6. doi: 10.1016/j.leukres.2011.01.004. Epub 2011 Feb 1. Leuk Res. 2011. PMID: 21281966

8

Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.

Martinez Marignac VL, Smith S, Toban N, Bazile M, Aloyz R. Martinez Marignac VL, et al. Among authors: aloyz r. Oncotarget. 2013 Dec;4(12):2550-66. doi: 10.18632/oncotarget.1508. Oncotarget. 2013. PMID: 24334291 Free PMC article.

9

Adaptive metabolic rewiring to chronic SFK inhibition.

Pinedo-Carpio E, Davidson D, Martinez Marignac VL, Panasci J, Aloyz R. Pinedo-Carpio E, et al. Among authors: aloyz r. Oncotarget. 2016 Mar 17;8(40):66758-66768. doi: 10.18632/oncotarget.8146. eCollection 2017 Sep 15. Oncotarget. 2016. PMID: 28977994 Free PMC article.

10

Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.

Davidson D, Coulombe Y, Martinez-Marignac VL, Amrein L, Grenier J, Hodkinson K, Masson JY, Aloyz R, Panasci L. Davidson D, et al. Among authors: aloyz r. Invest New Drugs. 2012 Jun;30(3):1248-56. doi: 10.1007/s10637-010-9626-9. Epub 2011 Jan 11. Invest New Drugs. 2012. PMID: 21221710

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters